Hints and tips:
Related Special Reports
Related Topics
...Bristol Myers Squibb raised $13bn in a large bond deal on Wednesday that will help fund two acquisitions....
...Bristol Myers Squibb launched a potentially jumbo-sized bond deal on Wednesday to help fund two acquisitions....
...Bristol Myers Squibb has agreed to buy neuroscience biotech Karuna Therapeutics for $14bn, gaining access to a promising schizophrenia drug....
...Bristol Myers Squibb has pushed out by one year its sales target for a new crop of drugs, guiding that the pharmaceutical company’s goal of at least $10bn would now not be achieved until 2026....
...Still, that has not stopped investors from fretting about pipeline replacement at companies such as Bristol Myers Squibb (BMS), Sanofi and Roche....
...Earnings: Aon, Bristol Myers Squibb, Danske Bank, Deutsche Bank, Electrolux, Ferrari and YouGov release results. Economic data: Monthly industrial production figures are to be published in France....
...Pharma: Pharmaceutical groups Bristol Myers Squibb, Regeneron and AbbVie will also report earnings before the market opens....
...Share moves to note on the New York Stock Exchange on Monday include Microsoft, Bristol Myers Squibb and Kohl’s: Microsoft hit a record high on Monday, with shares up 2.4 per cent in late afternoon trading...
...The impact could be significant for companies such as Bristol Myers Squibb. Its blood thinner Eliquis is expected to account for more than a quarter of sales in 2026, according to Visible Alpha....
...Bristol Myers Squibb trades on just seven times earnings while Pfizer is on 20 times. The frenzy for weight loss and diabetes medications is unlikely to fade....
...Oxford-based Exscientia is working with Sanofi and Bristol Myers Squibb, among others, and Insitro has a deal with Bristol Myers, while Owkin is also collaborating with Sanofi....
...Other earnings: Merck, Bristol Myers Squibb, UPS, Northrop Grumman, Honeywell, Altria, Hershey, Mastercard and Royal Caribbean report earnings before the opening bell....
...Bristol Myers Squibb said on Wednesday that chief executive Giovanni Caforio would step down as chief executive on November 1 and be replaced by chief commercialisation officer Christopher Boerner....
...High-grade pharma group Bristol Myers Squibb sold $13bn of debt on Wednesday....
...Mirati, which was purchased by Bristol Myers Squibb in a deal announced last year, did not immediately respond to a request for comment....
...Other drugmakers including Merck, Bristol Myers Squibb, and Johnson & Johnson, as well as the US pharmaceutical lobby group, have already filed lawsuits against the reforms....
...Myers Squibb would buy the biotech company....
...In the pharmaceutical industry, big companies including AstraZeneca, AbbVie and Bristol Myers Squibb have announced about $25bn worth of biotech-related deals....
...Johnson & Johnson joins the Merck, Bristol Myers Squibb and pharmaceutical lobby Pharmaceutical Research and Manufacturers of America in challenging the new law....
...The company joins Merck, Bristol Myers Squibb and the lobby group Pharmaceutical Research and Manufacturers of America in challenging the new law....
...Pharmaceutical groups Bristol Myers Squibb, Regeneron and AbbVie are also expected to release earnings....
...Bristol Myers Squibb told the FT last year it expected to cancel some drug programmes, with cancer medicines most vulnerable....
...A better look for the UK is GSK in a head-to-head with Bristol-Myers: This time, the UK company has stronger prospective earnings growth, due to Bristol’s patent expirations, as well as stronger returns...
...They include Eliquis, a blood thinner produced by Bristol Myers Squibb (BMS) and its partner Pfizer, the diabetes treatment Jardiance sold by Boehringer Ingelheim and Eli Lilly, and Xarelto, another blood...
International Edition